Markets:

Overview

News

Currencies

International

Treasuries

Vertex Pharmaceuticals (NQ:VRTX)

516.44 -9.29 (-1.77%)

Streaming Delayed Price Updated: 4:00 PM EDT, Aug 13, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Vertex Pharmaceuticals

< Previous 1 2 3 4 5 6 7 8 9

...

76 77 Next >

Vertex (VRTX) Q2 2026 Earnings Call Transcript ↗

August 10, 2026

Revenue hit $3.3 billion with guidance raised on strong newer product growth.

Via The Motley Fool

Topics Earnings

Discover which S&P500 stocks are making waves on Monday. ↗

August 10, 2026

Via Chartmill

Explore the top gainers and losers within the S&P500 index in today's session. ↗

August 10, 2026

Via Chartmill

Get insights into the top movers in the S&P500 index of Monday's pre-market session. ↗

August 10, 2026

Via Chartmill

Vertex Pharmaceuticals (NASDAQ:VRTX): Strong Growth and Textbooks Technical Setup for Breakout ↗

July 29, 2026

Via Chartmill

Vertex Pharmaceuticals (NASDAQ:VRTX): An Affordable Growth Stock Balancing Strong Fundamentals With Reasonable Valuation ↗

July 21, 2026

Via Chartmill

5 Insightful Analyst Questions From Vertex Pharmaceuticals’s Q2 Earnings Call

August 10, 2026

Vertex Pharmaceuticals’ second quarter reflected strong commercial momentum, with management highlighting the performance of its cystic fibrosis (CF) portfol...

Via StockStory

Topics Earnings

Could 1 Tiny Biotech Topple Vertex Pharmaceuticals' Cystic Fibrosis Empire? ↗

August 07, 2026

This risk is weighing on the stock.

Via The Motley Fool

Why Vertex Pharmaceuticals Stock Ticked Higher on Tuesday ↗

August 04, 2026

The company notched a pair of modest beats in its second quarter.

Via The Motley Fool

Vertex Pharmaceuticals Q2 Earnings Call Highlights ↗

August 03, 2026

Vertex Pharmaceuticals (NASDAQ:VRTX) reported second-quarter 2026 revenue growth of 12% year over year to $3.3 billion, driven by continued growth in its cystic fibrosis franchise and rising...

Via MarketBeat

Topics Earnings

Vertex Pharmaceuticals (NASDAQ:VRTX) Beats Q2 CY2026 Sales Expectations, Full-Year Outlook Slightly Exceeds Expectations

August 03, 2026

Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) announced better-than-expected revenue in Q2 CY2026, with sales up 12.5% year on year to $3.33 billion. ...

Via StockStory

Vertex Reports Second Quarter 2026 Financial Results

August 03, 2026

From Vertex Pharmaceuticals Incorporated

Via Business Wire

Vertex Pharmaceuticals (VRTX) Q2 Earnings Report Preview: What To Look For

August 01, 2026

Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) will be reporting results this Monday after the bell. Here’s what to look for. Vertex Pharmaceuticals be...

Via StockStory

Topics Artificial Intelligence

Vertex Just Paid $10 Billion for Crinetics. Here's Why Viking Therapeutics Could Be the Next Big Pharma Takeover Target ↗

July 30, 2026

There are other reasons to pay attention to Viking Therapeutics.

Via The Motley Fool

Morgan Stanley Nearly Doubled Its Price Target for CRISPR Therapeutics. Is the Gene-Editing Stock a No-Brainer Buy? ↗

July 30, 2026

The next six months may be decisive for the biotech.

Via The Motley Fool

AbCellera Announces Collaboration with Vertex to Discover Multispecific T-Cell Engagers for Autoimmune Diseases and Other Conditions

July 29, 2026

From AbCellera Biologics Inc.

Via Business Wire

3 Healthcare Stocks with Competitive Advantages

July 23, 2026

From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Players catalyzing medical advanceme...

Via StockStory

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: TriCo Bancshares (Nasdaq – TCBK), Twin Vee PowerCats Co. (Nasdaq -VEEE), Crinetics Pharmaceuticals, Inc. (Nasdaq – CRNX), Element Solutions Inc. (NYSE – ESI)

July 21, 2026

From Brodsky & Smith LLC

Via GlobeNewswire

Vertex Pharmaceuticals Just Made a $10 Billion Acquisition Worth Watching ↗

July 19, 2026

The biotech's diversification efforts continue.

Via The Motley Fool

Topics Intellectual Property

1 Nasdaq 100 Stock to Keep an Eye On and 2 We Question

July 16, 2026

The Nasdaq 100 (^NDX) is home to some of the biggest success stories in tech and growth investing. However, certain stocks in the index face challenges like ...

Via StockStory

$1000 Invested In Vertex Pharmaceuticals 5 Years Ago Would Be Worth This Much Today ↗

July 15, 2026

Vertex Pharmaceuticals (NASDAQ:VRTX) has outperformed the market over the past 5 years by 7.55% on an annualized basis producing an average annual return of 19.41%. Currently, Vertex Pharmaceuticals...

Via Benzinga

Here's Why Vertex Was Willing to Pay a Premium of More Than 100% for Crinetics Pharmaceuticals ↗

July 14, 2026

Vertex's $10 billion acquisition may have spooked investors, given how rich it appeared to be.

Via The Motley Fool

Does Vertex's Acquisition of Crinetics Pharmaceuticals Make the Stock a No-Brainer Buy? ↗

July 13, 2026

Vertex Pharmaceuticals recently announced its largest-ever acquisition.

Via The Motley Fool

Vertex Pharmaceuticals Bets $10 Billion on Crinetics to Build Endocrinology Powerhouse ↗

July 11, 2026

Vertex Pharmaceuticals (NASDAQ:VRTX) said it has entered into a definitive agreement to acquire Crinetics Pharmaceuticals for $85 per share in cash, a transaction Vertex executives described as a...

Via MarketBeat

Is This Biotech Stock a Buy Near Its 52-Week High? ↗

July 10, 2026

It's been a volatile year for the company, but don't let that scare you away.

Via The Motley Fool

Why This Pharmaceutical Stock Jumped Close to 100% This Week ↗

July 10, 2026

It is getting acquired by a larger firm in the sector.

Via The Motley Fool

Topics Bonds

3 Reasons to Buy CRISPR Therapeutics Stock ↗

July 10, 2026

The company's innovative qualities may pay rich dividends down the road.

Via The Motley Fool

Vertex Pharmaceuticals Just Made a $10 Billion Move. Is the Stock a Buy? ↗

July 10, 2026

Additional blockbuster drugs may be on the horizon.

Via The Motley Fool

Topics Intellectual Property

1 Momentum Stock to Research Further and 2 Facing Headwinds

July 09, 2026

Exciting developments are taking place for the stocks in this article. They’ve all surged ahead of the broader market over the last month as catalysts such a...

Via StockStory

Vertex’s Crinetics Deal Balances Growth with Integration Risk ↗

July 08, 2026

Vertex Pharmaceuticals will acquire Crinetics Pharmaceuticals for $10 billion at $85 per share, adding the approved drug PALSONIFY and pipeline candidate Atumelant to expand beyond its cystic fibrosis...

Via MarketBeat

< Previous 1 2 3 4 5 6 7 8 9

...

76 77 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.